Literature DB >> 7119381

[The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue].

R Morville, F Dray, J Reynier, J Barrat.   

Abstract

The effects of two galenic processes (micronisation and addition of oil) on the bioavailability of progesterone administrated orally were studied. After ingestion of progesterone (200 mg), mean plasma progesterone rapidly rises up to the 2nd hour and reaches levels of the normal luteal phase (12.6 +/- 2.6 ng/mg). It then decreases progressively up to the 8th hour. Daily administration of progesterone (300 mg) for 8 days significantly increases the endometrial concentration of the steroid (18.3 +/- 2.9 ng/ml) and efficiently corrects the tissular hormone deficiency. The breast tissue uptakes and concentrates equally progesterone. After oral administration of the natural hormone, progesterone concentrations are considerably increased in the three tissue compartments studied (normal glands: 25.0 +/- 9.7 ng/g; benign tumor: 38.0 +/- 9.1 ng/g; adipose tissue: 160.2 +/- 65.4 ng/g). These pharmaco-kinetic results correspond to the requirements of general substitutive hormone therapy. They justify the use of natural oral progesterone therapy, providing the amount given is modified according to immediate clinical tolerance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7119381

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  8 in total

1.  Progesterone and the premenstrual syndrome: a double blind crossover trial.

Authors:  L Dennerstein; C Spencer-Gardner; G Gotts; J B Brown; M A Smith; G D Burrows
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-01

Review 2.  The role of progestins in the behavioral effects of cocaine and other drugs of abuse: human and animal research.

Authors:  Justin J Anker; Marilyn E Carroll
Journal:  Neurosci Biobehav Rev       Date:  2010-04-14       Impact factor: 8.989

Review 3.  Progesterone for premenstrual syndrome.

Authors:  Olive Ford; Anne Lethaby; Helen Roberts; Ben Willem J Mol
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

4.  Progesterone in Peri- and Postmenopause: A Review.

Authors:  P-A Regidor
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-11       Impact factor: 2.915

5.  Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration.

Authors:  C Mircioiu; A Perju; E Griu; G Calin; A Neagu; D Enachescu; D S Miron
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

6.  Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration.

Authors:  C Mircioiu; A Perju; A Neagu; E Griu; G Calin; D S Miron
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

7.  Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease.

Authors:  C Nappi; P Affinito; C Di Carlo; G Esposito; U Montemagno
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

8.  Solubility Improvement of Progesterone from Solid Dispersions Prepared by Solvent Evaporation and Co-milling.

Authors:  Xing Chen; Ioannis Partheniadis; Ioannis Nikolakakis; Hisham Al-Obaidi
Journal:  Polymers (Basel)       Date:  2020-04-07       Impact factor: 4.329

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.